Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNAseq in BRD4 reporter KBM7 cells (REDS1 and REDS15) with SLC nucleoside transporter knockout 23 days post sgRNA transduction

ABSTRACT: To investigate the transcriptional profile in two BRD4 reporter clones (REDS1 and REDS15) after knocking out SLC35F5/29A4/28A3 for 23 days

ORGANISM(S): Homo sapiens

PROVIDER: GSE168101 | GEO | 2021/04/17

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

RNAseq in BRD4 reporter KBM7 cells (REDS1 and REDS15) with SLC nucleoside transporter knockout 23 days post sgRNA transduction

Project description:RNAseq in BRD4 reporter KBM7 cells (REDS1 and REDS15) with SLC nucleoside transporter knockout 23 days post sgRNA transduction

| PRJNA706020 | ENA

Cell-surface SLC nucleoside transporters and purine levels modulate BRD4-dependent chromatin states.

Project description: Not available

| S-EPMC7612075 | biostudies-literature

BRD4-chromatin interaction in reporter KBM7 cells (REDS15) with purine metabolism perturbation

Project description:To investigate whether BRD4-chromatin binding is modulated by purine levels, we performed BRD4 ChIP-seq in cells with SLC nucleoside transporters knockout, or cells with de novo purine synthesis inhibitor 6-MP treatment. (+)-JQ1, an inhibitor which disrupts BRD4 and acetylated histone binding, was used as a positive control.

2021-04-17 | GSE167374 | GEO

RNAseq in BRD4 reporter KBM7 cells (REDS1 and REDS15) with purine metabolism perturbation

Project description:To investigate the transcriptional profile in two BRD4 reporter clones (REDS1 and REDS15) with purine metabolism perturbation

2021-04-17 | GSE168099 | GEO

The expression profile of SLC transporter genes in resectable pancreatic cancer

Project description:Objectives: The aim of this study was to investigate the prognostic significance of thirteen anticancer drug-relevant solute carrier transporters (SLCs) in pancreatic cancer in the context of clinical-pathological characteristics and the KRAS mutation status of tumors. Methods: Tumors and non-neoplastic pancreatic tissues were obtained from 32 histologically verified patients with pancreatic ductal adenocarcinoma. The transcript profile of SLCs was assessed using quantitative real-time PCR. KRAS mutations in exon 2 were assessed by high resolution melting analysis and confirmed by sequencing. Results: SLC22A3 was upregulated and SLC22A1, SLC22A2, SLC22A11, SLC28A1, SLC28A3 and SLC29A1 were downregulated when compared with non-neoplastic pancreatic tissues. Moreover, significantly lower levels of SLC22A1, SLC22A11 and SLC29A1 were found in tumors with angioinvasion. There was also a significantly higher transcript level of SLC28A1 in tumors with regional lymph nodes affected by metastasis. The study found that a high expression of SLC22A1 or SLC28A1was significantly associated with poor overall survival in unselected patients. In contrast, a high expression of SLC22A3 or SLC29A3 was significantly associated with longer overall survival in patients treated with nucleoside analogs. Finally, SLC levels were not found to be associated with KRAS mutation status in exon 2. Conclusions: This study identified a number of associations of SLCs with prognosis of pancreatic cancer patients. Transcript levels of thirteen anticancer drug-relevant solute carrier transporters (SLCs) were determined by qPCR in pancreatic ductal adenocarcinomas and non-neoplastic tissue samples from 32 pancreatic cancer patients. MRPL19, ELF1 and POLR2A were used as reference genes for data normalization.

2013-06-30 | E-GEOD-47368 | biostudies-arrayexpress

The genetic landscape of the human solute carrier (SLC) transporter superfamily.

Project description: Not available

| S-EPMC6874521 | biostudies-literature

The expression profile of SLC transporter genes in resectable pancreatic cancer

2013-06-30 | GSE47368 | GEO

Taurine transporter (SLC6A6)-deficient skeletal muscle

Project description:Analysis of skeletal muscle from taurine transporter (TauT) knockout mice at 3 or 18 months of age. Knocking out TauT result in a decrease in muscle cell size, impaired exercise capacity and accelerated muscle aging. Results provide molecular insights into physiological role of taurine. Sample: 12

2014-05-08 | E-GEOD-57373 | biostudies-arrayexpress

The SLC transporter in nutrient and metabolic sensing, regulation, and drug development.

Project description: Not available

| S-EPMC6359923 | biostudies-literature

BRD4-chromatin interaction in reporter KBM7 cells (REDS15) with purine metabolism perturbation

Project description:BRD4-chromatin interaction in reporter KBM7 cells (REDS15) with purine metabolism perturbation

| PRJNA704409 | ENA